Use of radiofrequency ablation of the vaginal canal for genitourinary syndrome of menopause
The Journal of Sexual Medicine · 2025
DOI: 10.1093/jsxmed/qdae133 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The Journal of Sexual Medicine, 2025. Verfasst von Rodger Rothenberger und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of OB/GYN & Women's Health, Division of Female Pelvic Medicine and Reconstructive Surgery, The University of Louisville Medical Center, 55…. Hauptthemen laut MEDLINE: Vagina, Radiofrequency Ablation, Menopause. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 21 Literaturangaben.
Abstract (Originalsprache)
Background
Genitourinary syndrome of menopause (GSM) is a prevalent condition with a constellation of symptoms including burning, dryness, dyspareunia, and irritative lower urinary tract symptoms that result from vulvovaginal atrophic changes. Though hormonal therapy is a mainstay of treatment in GSM, some patients may pursue nonhormonal therapies.
Aim
To determine the efficacy of radiofrequency ablation of the vaginal canal with the MorpheusV applicator in reducing the symptoms of GSM.
Methods
We conducted a multicenter prospective case series of women with GSM as confirmed by Vaginal Health Index Score (VHIS). Subjects received 3 treatments of radiofrequency ablation ~4 weeks apart with follow-up to 6-month posttreatment. Outcomes The primary endpoint was VHIS at 6-month posttreatment. Secondary endpoints were VHIS at 3 months, Visual analog scale (VAS) pain with each treatment, 3- and 6-month measurements of urogenital distress inventory-6 (UDI-6), and female sexual function index (FSFI) questionnaires.
Results
From 2021 to 2023, 71 women were enrolled in the study with 51 followed to the 6-month follow-up time point. Treatments were found to be low in VAS pain score with mean values of 2.13 ± 2.1, 2.55 ± 2.38, and 2.18 ± 2.14 at treatments 1, 2, and 3 respectively. An improvement in VHIS score was seen from baseline to 3 months after the last treatment (15.00 ± 5.37 vs. 19.62 ± 4.44) and sustained at 6 months (20.23 ± 4.12) (P < .001). Significant improvements in both UDI-6 and FSFI were also noted. Between baseline and 6 months after treatment (FSFI: 18.81 ± 9.57 vs. 22.81 ± 10.34, P < 0.001; UDI-6: 39.58 ± 15.98 vs. 22.42 ± 14.03, P < 0.001). No adverse events were encountered by any subject during this study. Clinical implications A therapy that is safe and effective in the treatment of both GSM and lower urinary tract symptoms without the use of hormonal methods is clinically impactful for the many patients who cannot receive or do not desire to receive these medications. Strengths and limitations Strengths of this study include the utilization of 3 treatment sessions, with follow-up of subjects to 6-month posttreatment with a comprehensive assessment of patient symptoms. Limitations include the unblinded nature of the study and the lack of a comparator group.
Conclusion
The data from this study suggests that radiofrequency ablation of the vaginal canal by the MorpheusV applicator is a safe and effective intervention for GSM. It also shows subjective improvements in stress urinary incontinence, urge urinary incontinence, and sexual function.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of OB/GYN & Women's Health, Division of Female Pelvic Medicine and Reconstructive Surgery, The University of Louisville Medical Center, 550 South Jackson Street, Louisville, Kentucky 40202, United States.
- California Center for Female Pelvic Health and Sexual Wellness, 2121 East Coast Hwy, Suite #200, Corona Del Mar, CA, United States.
- Institute for Female Pelvic Medicine, 10133 Sherrill Blvd, Suite 100, Knoxville, TN, United States.
- Miklos and Moore Urogynecology and Cosmetic Vaginal Surgery, 11975 Morris Road, Suite 140, Alpharetta, GA 30005.
- Division of Female Pelvic Medicine and Reconstructive Surgery, The Christ Hospital, 6939 Cox Rd, Suite 271, Liberty Township, OH, United States.
Zitieren
APA
Rothenberger, R., Kopinga, E., Dell, J., Moore, R. D., Miklos, J. R., & Karram, M. (2025). Use of radiofrequency ablation of the vaginal canal for genitourinary syndrome of menopause. The Journal of Sexual Medicine. https://doi.org/10.1093/jsxmed/qdae133
Vancouver
Rothenberger R, Kopinga E, Dell J, Moore RD, Miklos JR, Karram M. Use of radiofrequency ablation of the vaginal canal for genitourinary syndrome of menopause. The Journal of Sexual Medicine. 2025. doi:10.1093/jsxmed/qdae133
BibTeX
@article{Rothenberger2025,
author = {Rothenberger, Rodger and Kopinga, Elaine and Dell, Jeffrey and Moore, Robert D and Miklos, John R and Karram, Mickey},
title = {Use of radiofrequency ablation of the vaginal canal for genitourinary syndrome of menopause},
journal = {The Journal of Sexual Medicine},
year = {2025},
doi = {10.1093/jsxmed/qdae133}
}
EUVIMED